Objective: Aprotinin is frequently used to reduce blood loss during cardiac surgery; however, it also causes renal injury. Since aprotinin reduces nitric oxide (NO) and prostaglandin I 2 (PGI 2 ), and both cause vasodilation and inhibit activation of neutrophils and platelets, their reduction may be responsible for the injury. This study was to determine whether the combination of aprotinin with NO and prostaglandin E 1 (PGE 1 , an analogue of PGI 2 ) can attenuate renal injury associated with aprotinin during cardiopulmonary bypass (CPB). Methods: Thirty mongrel dogs were equally divided into five groups, with each group receiving CPB and aprotinin, NO, PGE 1 , a combination of the three or no treatment (control). Serum creatinine and creatinine clearance were determined. To elucidate the mechanism, neutrophil, platelet and thrombin activations were also assessed. Results: After CPB, serum creatinine increased and creatinine clearance decreased in all dogs. These changes were similar among the NO, PGE 1 , aprotinin and control groups, but were significantly smaller in the combination group. Similarly, myeloperoxidase activities in tissues, CD11b expression, plasma elastase, prothrombin fragment (PTF) 1 + 2 and platelet activation factor were lower, whereas neutrophil and platelet counts were higher in the combination group than in the other groups (P < 0.05). Conclusions: Aprotinin combined with NO and PGE 1 produced synergistic protective effects and improved renal function, due partly to inhibition of platelet and neutrophil activation and suppression of thrombin formation. #
Introduction
Postoperative haemorrhage is a major clinical challenge of cardiovascular surgery, and its complications include high consumption of blood products, prolonged intensive care hospitalisation and increased mortality and morbidity [1] . Pharmacologic intervention is, therefore, required to minimise blood loss during cardiac surgery. Aprotinin, a nonspecific serine proteinase inhibitor derived from bovine lung, was approved by the Food and Drug Administration (FDA) in 1993. It reduces blood loss in a dose-dependent manner. Cochrane reviews [2] and meta-analysis studies [3] reported that high doses of aprotinin significantly reduce blood transfusion, blood drainage and re-operation due to bleeding when compared with other anti-fibrinolytic agents, such as tranexamic acid or aminocaproic acid. Unfortunately, at these doses, aprotinin also increases the risk of renal failure, myocardial infarction, stroke and death from cardiac causes [4, 5] , especially in high-risk cardiac surgery [6] . Furthermore, in a multicentre image study [7] , the occlusion rate of saphenous grafts was higher with aprotinin therapy (15%) than in controls (11%). These data suggest that aprotinin may increase organ dysfunction and promote thrombus formation. Aprotinin not only inhibits fibrinolysis but also reduces PGI 2 [8] , bradykinin [9] and endothelial nitric oxide (NO) [10] . These substances, particularly NO and prostaglandin I 2 (PGI 2 ), cause vasodilatation and inhibit neutrophil and platelet activation by stimulating intracellular cyclic guanosine monophosphate and cyclic adenosine monophosphate. During cardiopulmonary bypass (CPB), aprotininrelated decreases in NO and PGI 2 may aggravate inflammation via neutrophil and platelet coagulation. The interaction between neutrophils and platelets may amplify inflammation and coagulation, resulting in organ injury [11] and may explain why aprotinin is associated with a higher risk of microvascular and macrovascular thrombosis. Because of its high affinity for the kidney [12] , aprotinin may preferentially cause renal dysfunction. In the present study, we hypothe-sised that aprotinin combined with NO inhalation and prostaglandin E 1 (PGE 1 , an analogue of PGI 2 ) injection will attenuate renal injury associated with aprotinin during CPB.
Materials and methods

Surgical procedure
After approval by the local animal Ethics Committee, 30 adult mongrel male dogs, weighing 20-25 kg, were anaesthetised with sodium pentobarbital (25 The heart was exposed through a mid-sternal incision. After heparinisation (3 mg kg À1 ), the ascending aorta and the right atrial appendage were cannulated. The CPB circuit was composed of a rolling pump (Stöckert II, Munich, Germany), bubble oxygenator (95 type; Xi-Jing Medical Ltd., Xi'an, China) and an arterial filter. The CPB was primed with Ringer's lactate solution (750 ml), 6% voluven (750 ml), heparin (20 mg) and 5% sodium bicarbonate (50 ml). The activated coagulation time was maintained for more than 480 s throughout the perfusion. A double-lumen cardioplegic catheter was inserted into the ascending aorta for delivery of hyperkalaemic blood 10 min after onset of CPB. The aortic cross-clamp was released after the heart was arrested for 60 min. The dogs were weaned from CPB after 30 min of reperfusion and observed for 6 h. After the experiments, the dogs were sacrificed with a bolus of i.v. sodium pentobarbital (120 mg kg À1 ).
Experimental protocol
After CPB set-up, the dogs were randomly divided into five groups, with six dogs in each group. In the aprotinin group, each dog received full Hammersmith dose of 8000 KIU /kg (kallikrein inhibitor units) of aprotinin (Livzon Pharmaceutical Trading Co., Zhuhai, China). One-half was given as a loading dose in the priming solution, and the rest was given as a continuous i.v. infusion throughout CPB. Dogs in the NO group were given 40 ppm NO (Beijing Beiyang Lianhe Qiti Co., Ltd.) by inhalation from the bubble oxygenator (monitored by NOxBOX W+ from Bedfont Scientific Ltd.) throughout CPB. In the PGE 1 group, 20 ng kg À1 min À1 of PGE1 (Pukang Pharmaceutical Co., Nanyang, China) was given to each dog via the oxygenator during CPB. The three interventions were combined in the aprotinin, NO and PGE 1 group, and the control group received no treatment during CPB. The anaesthesiologists, surgeons and laboratory staff were blinded throughout the study.
Renal function
Renal function was assessed by serum creatinine levels and creatinine clearance (Ccr). Urine outputs were measured during and after CPB. Blood and urine samples were collected for the analysis of creatinine on an automated analyser at 0, 3 and 6 h after CPB. Ccr was calculated by using the following equation:
Ccr ¼ ðurine creatinine Â urine volumeÞ plasma creatinine
Blood cell counts and biochemical indices in plasma
Blood samples were drawn from the femoral venous line at 0, 3 and 6 h after CPB for blood cell analysis by a haematology automated analyser (Sysmex XE-2100, Sysmex Corporation, Nishi-ku, Japan). At the same time points, samples from the femoral vein were heparinised for analysing biochemical indices. They were centrifuged at 3000 rpm for 5 min at 4 8C. The plasma was transferred to another tube and immediately frozen and stored at À70 8C.
The plasma levels of elastase, platelet-activating factor (PAF) and prothrombin fragment 1 + 2 (PTF 1 + 2) were quantitatively determined by enzyme immunoassay developed by Bionewtrans Pharmaceutical Biotechnology Co., Ltd. (Franklin, MA, USA).
Flow cytometry analyses of CD11b
Leucocytes from femoral venous blood samples were diluted to 1 Â 10 6 cells ml À1 . Cells were incubated with purified monoclonal antibody CD11b mouse IgG1 (Serotec, MorphoSys UK Ltd., Oxford, UK) at 4 8C for 1 h. After washing three times with phosphate-buffered saline (PBS), the cells were incubated with rabbit anti-mouse secondary fluorescein isothiocyanate (FITC) conjugate (Serotec, MorphoSys UK Ltd.) for 30 min at 4 8C. Thereafter, the cells were washed twice and analysed using a flow cytometer (Esp Elite; Beckman Coulter, Chicago, IL, USA).
Neutrophil sequestration in tissues
Myeloperoxidase (MPO) in tissues was analysed for the determination of neutrophil accumulation. At the end of the experiments, tissue samples, weighing about 0.4 g each, were taken from the upper pole of the kidney, homogenised and dissolved in potassium phosphate. After centrifugation, supernatants were collected in phosphate buffer. The MPO levels were measured by enzyme immunoassay developed by Bionewtrans Pharmaceutical Biotechnology Co., Ltd.
Statistical analysis
All values are expressed as the mean AE standard deviation (SD). Statistical comparison was performed by one-way analysis of variance (ANOVA) using an SPSS software program (SPSS Inc, Chicago, IL, USA) with significance defined as P < 0.05. If significance was found, Tukey's post hoc test was applied to locate the source of differences.
Results
Renal dysfunction was lessened by aprotinin combined with NO and PGE1
Renal dysfunction demonstrated by increased serum creatinine levels and decreased Ccr was observed after CPB in all groups (Fig. 1) . Severity of renal dysfunction did not differ among the aprotinin, NO, PGE 1 and control groups. In the current study, aprotinin did not show apparent renal damage. Renal dysfunction was only slightly decreased in the NO and PGE 1 combination treatment (Fig. 2) , and was significantly alleviated by the addition of aprotinin (aprotinin combined with NO and PGE1, Fig. 1 ).
Neutrophil activation was suppressed by the combination treatment
Systemic inflammation, especially neutrophil infiltration in renal tissues, causes renal injury during cardiac surgery. To investigate the role of inflammation, MPO as an index of neutrophil accumulation was measured. MPO activity was significantly lower after combination treatment than in any other group (Fig. 3) . Neutrophil counts (Fig. 4(A) ) increased after CPB in all groups (P < 0.05 vs after induction), and the increments were similar in the aprotinin, NO, PGE 1 and control groups, but were significantly higher in the combination group. However, plasma neutrophil elastase levels were significantly lower in the combination group than in the other groups (P < 0.01 vs the other four groups; Fig. 4(B) ). No difference was found in plasma elastase levels among the aprotinin, NO, PGE 1 and control groups (P > 0.05).
The inhibition of neutrophil activation by combination treatment was confirmed in the flow cytometry study. Mean fluorescent intensities of CD11b, an adhesion molecule expressed on activated leucocytes, were significantly lower in the combination group than in the other four groups (P < 0.01, Fig. 5 ). Again, there were no differences among the aprotinin, NO, PGE1 and control groups.
Inhibition of platelet activation by the combination treatment
Decreased platelet counts and increased plasma PAF levels were observed in all the groups after CPB (P < 0.01; Fig. 1 . Effects of different treatments on renal function in five groups of dogs (n = 6 each). Serum creatinine levels increased, and creatinine clearance (Ccr) decreased in all groups after CPB, and there was no difference between the control and aprotinin groups. Aprotinin combined with NO and PGE 1 (A + N + P group) significantly improved serum creatinine and Ccr in comparison to the other four treatments. In the aprotinin group, each dog received 8000 KIU /kg of aprotinin. Dogs in the NO group were given 40 ppm nitric oxide throughout the CPB. In the PGE 1 group, 20 ng kg À1 min À1 of prostaglandin E 1 was given throughout the CPB. Dogs in A + N + P group were given 40 ppm NO by inhalation, 20 ng kg À1 min À1 of PGE1 and 80,00 KIU /kg aprotinin by infusion. The control group did not receive any treatment. *, P < 0.05; **, P < 0.01 versus the other four groups; # , P < 0.01, and z , P < 0.05 versus after induction. Fig. 2 . Renal function assessment in three groups of dogs. In the N + P group (n = 4), each dog was given 40 ppm NO by inhalation and 20 ng kg À1 min À1 of PGE 1 by infusion throughout the CPB. Dogs in the A + N + P group were treated additionally with 8000 KIU /kg aprotinin. The control group did not receive any treatment. Serum creatinine levels were lower and creatinine clearances were higher in the A + N + P group when compared with the N + P group, suggesting aprotinin plays an important role in the synergistic protection of the kidney. *, P < 0.01 versus control; $, P < 0.05 versus control; D, P < 0.01 versus N + P; # , P < 0.01, and z , P < 0.05 versus after induction. Fig. 3 . Myeloperoxidase (MPO) contents of renal tissues. Data were expressed by the mean AE standard deviation. MPO is an index of neutrophil accumulation in tissues. MPO activity was significantly lower in the combination group (A + N + P) than in the other four groups. *, P < 0.05 versus other groups (n = 6 each). Fig. 6 ). Aprotinin slightly improved platelet counts 6 h after CPB, although it did not reach statistical significance compared with the control group (P = 0.058). The combination treatment of aprotinin with NO and PGE 1 , however, improved platelet counts significantly (P < 0.05; Fig. 6(A) ). PAF is released from activated platelets. In the present study, plasma PAF levels were lower in the aprotinin-treated group than in the control, NO and PGE 1 groups (P < 0.05), and further decreased in the combination treatment group (P < 0.05; Fig. 6(B) ). These results suggest effective inhibition on platelet activation by aprotinin combined with NO and PGE 1 . As thrombin is a potent platelet activator, PTF 1 + 2 was also measured to assess the thrombin formation. PTF 1 + 2 level in the plasma was lower in the aprotinin group, and still lower in the combination group than in the control, NO and PGE 1 groups (P < 0.05; Fig. 7 ).
Discussion
In this CPB study, using serum creatinine and Ccr to assess renal damage, aprotinin did not show apparent renal impairment. On the contrary, when combined with NO and PGE 1 , aprotinin prevented CPB-induced renal dysfunction and decreased CD11b expression, leucocyte sequestration in the kidney, plasma elastase, PAF and PTF 1 + 2.
Aprotinin as the cause of renal toxicity has been questioned for decades [13] . Aprotinin has been reported to increase postoperative serum creatinine [2] , the need for dialysis [4] and mortality in cardiac surgical patients [5, 6] . However, other studies show that aprotinin does not increase the risk of renal injury [14] [15] [16] . These differences may result from variations in exclusion criteria, or in how renal function is defined or in patient selection. Aprotinin is used in patients with haemorrhagic tendency because of its ability to minimise bleeding [2, 17] , which may explain the higher morbidity in aprotinin users. Our current experiments were designed to eliminate variance, and the results showed no difference in renal function between the aprotinin and control groups (Fig. 1) .
The cause of renal dysfunction following cardiac surgery is multifactorial, including decreased renal perfusion, lack of pulsatile perfusion during CPB, inflammatory response and microthrombus [18] . Aprotinin might aggravate renal injury by inhibiting kallikrein and endogenous vasodilators, such as PGI 2 [8] and NO [9, 10] , because both of them are important regulators of vascular tone and tissue perfusion. In this study, the severity of renal dysfunction was similar in aprotinin and control groups. The dysfunction was slightly alleviated by the combination of two vasodilators (NO and PGE 1 ), and was significantly alleviated by the addition of aprotinin to NO and PGE 1 . The results suggest that reduced renal blood flow is not Fig. 4 . Both neutrophil counts (A) and plasma elastase levels (B) increased after CPB, and were similar in the control, NO, PGE 1 , and aprotinin groups throughout the experiment. Aprotinin combined with NO and PGE 1 (A + N + P) induced a further increase in neutrophil counts and a decrease in plasma neutrophil elastase levels after CPB. *, P < 0.05 versus other groups (n = 6 in each group); # , P < 0.01, and z , P < 0.05 versus after induction. Fig. 5 . Effects of different treatments on mean fluorescence intensity of CD11b. Data were expressed by the mean AE standard deviation. Fluorescence intensities increased over 10 times from the baseline after completion of CPB and 6 h thereafter in aprotinin, NO, PGE 1 , and control groups. Flourescence increased only 5-6 times when the dogs were treated with aprotinin combined with NO and PGE 1 (A + N + P). **, P < 0.01 compared with aprotinin, NO, PGE 1 , and control groups. . Effects of different treatments on platelet counts and plasma levels of platelet-activating factor in five groups of dogs. Platelet counts significantly decreased, while platelet-activating factor levels increased after CPB. Both were significantly improved by combination treatment (A + N + P). *, P < 0.05 versus aprotinin, or NO, or PGE 1 , or control group, D, P < 0.05 versus NO, or PGE 1 or control group; and # , P < 0.01 versus after induction.
the main reason for CPB-induced renal injury and combination of the three agents may provide a synergistic, protective effect on the kidney. Our data do not show that aprotinin causes renal dysfunction. Although serum creatinine and Ccr are the most commonly used tests to assess renal function, they are insensitive indicators of tubular injury. Nevertheless, our data do demonstrate that aprotinin plays the most important role among the three agents tested in alleviating CPB-induced renal dysfunction. Inflammatory response and coagulation cascade are initiated during CPB [18] . They are two intricate, crosslinked processes in defending injuries [11] . The interaction between inflammation and coagulation [19] facilitates organ injury during CPB. Neutrophil activation is one of the typical characters in CPB-induced systemic inflammatory response. The activated neutrophils adhere to the endothelium via interaction of CD11b/CD18 (Mac-1) and intercellular adhesion molecule-1(ICAM-1), and then destroy tissues by releasing proteolytic enzymes [20] . Although NO, PGE 1 and aprotinin are all reported to inhibit neutrophils, only aprotinin combined with NO and PGE 1 significantly reduced CD 11b expression on leucocytes and the sequestration of neutrophils in tissues and plasma elastase. This suggests that their synergistic effect on renal protection may be due to their synergistic suppression on neutrophils during CPB. Aprotinin may play an important role, which is supported by previous studies in which aprotinin reduced myocardial [21] and lung [22] injury during reperfusion by a dose-dependent decrease in neutrophil activation.
Thrombin, a serine protease, is a key enzyme during coagulation, and also mediates inflammation by activating endothelial cells [23] , leucocytes [24] and platelets [23] via protease-activated receptors. The interaction among these activated cells induces leucocyte sequestration in tissues. In the present study, we found that aprotinin reduced thrombin formation and increased platelet counts. These effects may be mediated by intrinsic and extrinsic coagulation pathways and monocyte expression of tissue factor [25] . Reduced thrombin formation decreases the stimuli on platelets and endothelial cells by inhibiting the activation of proteaseactivated receptor 1 [25] . Combined with potent inhibitors of neutrophil and platelet (NO and PGE 1 ), aprotinin may effectively reduce the interaction among platelets, endothelial cells and neutrophils, thus reducing neutrophil sequestration.
Limitations
The investigation was carried out for 6 h after CPB. Thus, the data obtained can only be used to assess acute effects. However, aprotinin can accumulate within the cytoplasm, and increase mortality, even 5 years after its use [8] . Therefore, further studies are needed for the long-term assessment of this combination therapy.
In conclusion, our CPB studies demonstrate that aprotinin does not produce detrimental effects, but improves renal function when combined with NO and PGE 1 . One possible explanation is that together they synergistically suppress activation of neutrophils and platelets, and reduce thrombin formation. Fig. 7 . Plasma levels of prothrombin fragment 1 + 2 (PTF 1 + 2) were increased by CPB, but the increment was smaller in the aprotinin treatment group, and even more than in the combination treatment group (A + N + P group). D, P < 0.05 compared with the control, NO, and PGE 1 groups, # , P < 0.01, and z , P < 0.05 versus after induction.
